Skip to main content
TipRanks
Go Ultimate75% OFF

Citius Oncology (CTOR) Stock Price & Analysis

132 Followers

CTOR Stock Chart & Stats

$0.54-$0.04(-6.63%)
At close: 4:00 PM EST
$0.5$0.75$1Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.53 - $0.58
52-Week Range
$0.49 - $1.83
Previous Close
$0.57
Volume
N/A
Average Volume (3M)
133.81K
Market Cap
$49.74M
Enterprise Value
$63.79M
Total Cash (Recent Filing)
$16.56M
Total Debt (Recent Filing)
$10.21M
Price to Earnings (P/E)
―
Beta
2.92
Next Earnings
Dec 17, 2026 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

LYMPHIR Demand Growth

Rapidly increasing wholesaler purchases and institutional participation indicate that LYMPHIR is gaining commercial traction beyond an initial launch. If this ordering pattern persists, it can build a broader prescribing base and create a foundation for recurring product revenue over the next several quarters.

Expanding Market Access

Broad institutional availability, formulary inclusion, and near-universal payer coverage reduce practical barriers to treatment adoption. These access characteristics support continued account expansion and improve the likelihood that commercial demand can translate into sustained patient starts and repeat orders.

Low Financial Leverage

Very low leverage gives Citius Oncology more balance-sheet flexibility than a highly indebted development-stage company. Although it remains loss-making, limited debt reduces interest and refinancing pressure, allowing management to direct more resources toward commercialization and clinical development.

Bears Say

Persistent Operating Losses

The company has not yet established a reported annual revenue base in the provided financial periods, while operating losses have widened substantially. This creates a fragile earnings profile in which future financial performance depends heavily on successful commercialization and rapid conversion of launch activity into revenue.

Increasing Cash Burn

Worsening operating and free cash flow indicate that the business is consuming increasing amounts of cash while building its commercial platform. Unless product revenue improves materially, continued burn may require additional financing and could constrain investment or dilute existing shareholders.

Nasdaq Compliance Risk

The compliance extension postpones rather than resolves the listing issue. Failure to regain the required bid price could begin a delisting process, potentially reducing market access and liquidity and complicating the company’s ability to use its public listing for future financing.

Citius Oncology News

CTOR FAQ

What was Citius Oncology’s price range in the past 12 months?
Citius Oncology lowest stock price was $0.49 and its highest was $1.83 in the past 12 months.
What is Citius Oncology’s market cap?
Citius Oncology’s market cap is $49.74M.
When is Citius Oncology’s upcoming earnings report date?
Citius Oncology’s next earnings report is estimated for Dec 17, 2026 (not yet confirmed), which is in 30 days.
How were Citius Oncology’s earnings last quarter?
Citius Oncology released its earnings results on Aug 14, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.01.
Is Citius Oncology overvalued?
According to Wall Street analysts Citius Oncology’s price is currently Undervalued.
Does Citius Oncology pay dividends?
Citius Oncology does not currently pay dividends.
What is Citius Oncology’s EPS estimate?
Citius Oncology’s EPS estimate is -0.07.
How many shares outstanding does Citius Oncology have?
Citius Oncology has 92,981,200 shares outstanding.
What happened to Citius Oncology’s price movement after its last earnings report?
Citius Oncology reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -18.592%.
Which hedge fund is a major shareholder of Citius Oncology?
Hedge funds hold Citius Oncology shares: the largest hedge-fund position in Citius Oncology is 71,888,482 shares, and hedge funds decreased their holdings by 47.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology